Lanean...
CD30-targeting drugs: cure for mastocytosis?
New promising targets and targeted drugs for treatment of aggressive forms of systemic mastocytosis are few; in this issue of Blood, Blatt et al(1) provide evidence that aberrant Ki-1 antigen (CD30) expression on neoplastic mast cells may serve as a therapeutic target of brentuximab-vedotin alone or...
Gorde:
| Argitaratua izan da: | Blood |
|---|---|
| Egile nagusia: | |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
American Society of Hematology
2015
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4692137/ https://ncbi.nlm.nih.gov/pubmed/26705339 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-11-678631 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|